• A Company Dedicated to Safe Therapeutic Modulation of Monoamine Neurotransmitter

    Read more

  • Interim Report
    January – September 2021

    Read the report

Press releases

Older releases

Latest reports

All reports

Calendar

All events

Share

Read more

Initiator Pharma Numbers

  • Number of men affected by Erectile Dysfunction worldwide 150 million
  • Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 150000
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiatorpharma-module-homepage-1-22102021

Initiator Pharma currently has a portfolio of four projects, of which two are in clinical development and two are in preclinical development.

View our Pipeline

CEO letter

The future looks very exciting, and our three clinical-stage programs will all have upcoming key value inflection points in the form of Phase 2 data read-outs over the next couple of years. As always, I look forward to keeping you informed on the clinical development of our portfolio.

Read the full letter
Initiatorpharma-module-homepage-2-22102021

Mono-amine transporters is a unique class of proteins that are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron.

Read more about our technology